Research and Development Investment: TG Therapeutics, Inc. vs Soleno Therapeutics, Inc.

Biotech R&D: TG Therapeutics vs Soleno Therapeutics

__timestampSoleno Therapeutics, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 2014224221631354781
Thursday, January 1, 2015453624443445817
Friday, January 1, 2016518480366489820
Sunday, January 1, 2017306874296886134
Monday, January 1, 20187178000153793000
Tuesday, January 1, 201916267000148369000
Wednesday, January 1, 202023191000151934000
Friday, January 1, 202121453000198532000
Saturday, January 1, 202215265000112128000
Sunday, January 1, 20232518900076192000
Loading chart...

Infusing magic into the data realm

A Decade of R&D Investment: TG Therapeutics vs Soleno Therapeutics

In the competitive landscape of biotechnology, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, TG Therapeutics, Inc. and Soleno Therapeutics, Inc. have demonstrated contrasting investment strategies in R&D.

From 2014 to 2023, TG Therapeutics consistently outpaced Soleno Therapeutics, with an average annual R&D expenditure nearly nine times higher. Notably, in 2021, TG Therapeutics peaked with an investment of approximately $198 million, reflecting a 530% increase from 2014. In contrast, Soleno Therapeutics' R&D spending grew by 1,024% over the same period, reaching its highest in 2023 with $25 million.

These figures highlight TG Therapeutics' aggressive pursuit of innovation, while Soleno Therapeutics shows a steady, albeit smaller, commitment to R&D. This divergence in strategy underscores the varied approaches companies take in the biotech sector to drive growth and development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025